FDA PMTA overhaul talk draws VTA reform push as no rule text is published

The FDA wants a more predictable PMTA process, but as of the RegWatch episode released on 4 November 2026, no replacement rule, draft text or deadline has been published. The Vapor Technology Association is using that opening to press for clear scientific standards.

Tony Abboud, who leads the VTA, set out the case for reform in the episode, linking it to the campaign to preserve flavoured vaping products in the US market. His argument, as presented, rests on standards companies can plan against rather than shifting expectations.

What the FDA has actually signalled, and what it has not

The signal is an intention: a PMTA process that behaves more predictably. The source material carries no proposed rule, no statutory citation and no date on which anything would change.

For operators, that distinction matters. Until a rule is proposed and then finalised, applications continue to be assessed under the pathway already in place. VapeBrief found nothing in the available material that identifies which parts of the process the agency would alter.

Denials and shifting standards are the complaint

The critique aired in the episode is that companies have faced years of changing requirements, mass denials of applications and a prolonged wait for decisions. That combination, the VTA argues, leaves businesses unable to plan.

Commentary carried by Nicotine Science and Policy makes a parallel point: a pathway that traps products in uncertainty while cigarettes stay legally available and illicit alternatives take shelf space serves nobody. That outlet argues the system should be rigorous, transparent and quick enough to separate responsible products from those that fall short.

The two accounts agree on the problem, not the remedy

Both sources describe a process they consider too slow and too unpredictable. Neither sets out the mechanism, scope or timing of a replacement.

Who carries the cost of an unchanged process

US manufacturers and importers of nicotine products remain the parties required to file premarket applications, and they absorb the cost of every round. Distributors and retailers carry the downstream risk: a product that loses its authorisation cannot stay on sale.

Brands that built ranges around flavoured products have the most exposure to how standards are written, given the VTA’s stated focus on saving flavoured vaping. The material does not identify which product categories or flavours would be covered by any revised framework.

Companies outside the US are affected only where they sell into that market or supply American partners. The sources mention no other jurisdiction.

What would make the signal concrete

A published proposal would be the first verifiable step, and none appears in the material. Without it, talk of a reset stays a statement of intent from the agency and a lobbying objective for the association.

Retailers and distributors should treat the existing PMTA requirements as the binding rules and watch for a formal Federal Register notice or draft guidance. The sources give no date for such a step, so no compliance calendar can be built from them yet.

Questions readers ask

Has the FDA changed the PMTA process?

The available material describes an FDA signal of intent to make the process more predictable. It contains no proposed rule, final rule or effective date, so the existing pathway remains the stated basis for applications.

What does the Vapor Technology Association want?

Tony Abboud presented the VTA case for clear scientific standards in premarket review, tied to the campaign to save flavoured vaping products. The material does not set out specific criteria.